Opterion Health AG Announces Positive Phase 1 Results for OPT101

MUTTENZ, Switzerland, Sept. 22, 2026 /CourierPR/ -- Opterion Health AG, a Swiss clinical-stage biotechnology company, has announced positive Phase 1 results for its investigational non-glucose-based osmotic driver solution, OPT101. The SPARC study, the first-in-human Phase 1 clinical trial, evaluated the solution in patients with moderate to severe chronic kidney disease. The results have bolstered confidence in OPT101, demonstrating its safety, tolerability, and functional activity.

SPARC tested different concentrations of OPT101 in four-hour and eight-hour dwell periods. The study showed no serious adverse events, treatment discontinuations, dose interruptions, or concentration-limiting toxicities. OPT101 demonstrated significant fluid and sodium removal across all evaluated concentrations, with the highest concentration producing the greatest mean fluid removal in both short and long dwells. These findings support the advancement of OPT101 to Phase 2a, where the company plans to evaluate repeated administration, dose selection, and broader dwell replacement.

Peritoneal dialysis allows people with kidney failure to receive life-sustaining treatment at home. However, patients still rely heavily on glucose-based solutions that can contribute to metabolic complications, weight gain, and damage to the peritoneal membrane over time. Existing non-glucose alternatives cannot cover both short and long dwells, limiting treatment choice and adding complexity to an already demanding daily routine.

OPT101 is being developed as a differentiated, non-glucose-based solution for both short and long dwells. No currently available solution offers the same intended combination of non-glucose-based treatment, concentration flexibility, and use across both dwell settings. The Phase 1 SPARC results demonstrated a favorable safety and tolerability profile, as well as encouraging exploratory evidence of fluid and sodium removal in patients with moderate to severe chronic kidney disease.

The global peritoneal dialysis market is estimated to be worth approximately USD 11.5 billion in 2025 and is projected to reach USD 21.5 billion by 2034, representing a compound annual growth rate of approximately 7.2%. Despite offering important clinical and lifestyle advantages, peritoneal dialysis accounts for only around 12% of dialysis patients globally. As rising rates of chronic kidney disease and diabetes increase pressure on healthcare systems, the market is expected to continue expanding.

Opterion Health AG is led by a highly experienced team in global dialysis, bringing together decades of expertise across renal care, clinical development, commercialization, and healthcare operations. The company's lead program, OPT101, has successfully completed Phase 1 clinical evaluation and is being developed to address longstanding limitations of conventional peritoneal dialysis therapy, with the goal of expanding treatment choice and enabling more patients to benefit from home-based dialysis.